Improving diagnosis and treatment for advanced ovarian cancer
Integration of Multiple Data Levels to Improve Diagnosis, Predict Treatment Response and Suggest Targets to Overcome Therapy Resistance in High-grade Serous Ovarian Cancer
This study is testing personalized treatment plans for newly diagnosed advanced ovarian cancer patients who may not respond well to standard chemotherapy to see if it can improve their outcomes.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Turku University Hospital Government |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Turku) |
| Trial ID | NCT04846933 on ClinicalTrials.gov |
What this trial studies
This study aims to address chemotherapy resistance in high-grade serous ovarian cancer (HGSOC) by developing personalized treatment regimens for patients who are likely to respond poorly to standard therapies. It involves recruiting newly diagnosed advanced stage HGSOC patients and utilizing advanced techniques such as whole genome sequencing, RNA sequencing, and circulating tumor DNA analysis. The study will also integrate digital pathology and clinical data with AI methods to identify mechanisms of resistance and suggest targeted therapies. The ultimate goal is to enhance clinical decision-making and improve patient outcomes through personalized medicine approaches.
Who should consider this trial
Good fit: Ideal candidates for this study are newly diagnosed advanced stage HGSOC patients treated at Turku University Hospital.
Not a fit: Patients under 18 years old or those in too poor a condition for active treatment will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective, personalized treatment options for patients with chemotherapy-resistant ovarian cancer.
How similar studies have performed: Other studies have shown promise in using personalized medicine approaches for cancer treatment, suggesting potential success for this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with a suspected ovarian cancer diagnosis treated at the Turku University Hospital * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Age \<18 years, too poor condition for active treatment (surgery, chemotherapy) * FDG PET/CT scan is not performed for patients with diabetes mellitus and poor glucose balance.
Where this trial is running
Turku
- Turku University Hospital — Turku, Finland (Recruiting)
Study contacts
- Principal investigator: Johanna Hynninen, MD, PhD — Turku University Hospital
- Study coordinator: Johanna Hynninen
- Email: johanna.hynninen@utu.fi
- Phone: +358 50 5383554
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.